Pear Therapeutics Obtains First Medicaid Coverage For PDTs
Massachusetts’ Medicaid program will cover reSET and reSET-O prescription digital therapeutics for the treatment of substance abuse disorder and opioid use disorder.
You may also be interested in...
Pear Therapeutics is restructuring itself to lower costs following repeated disappointing performances.
Availability of Spanish-language prescription digital therapeutics for the treatment of substance use disorder and opioid use disorder will address important health equity and health care disparities, according to Pear.
Medtech Insight spoke to Pear Therapeutics CEO Corey McMann about the emerging digital therapeutics market and his company’s future now that it has the first PDT covered by Medicaid.